Dianthus Therapeutics (DNTH) PT Raised to $130 at H.C. Wainwright
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/8/2026
- Wall St turns lower as crude spikes, chip stocks weigh
- Oil jumps 5%, then pares gains after Trump says no attack on Iran this month
- Chipotle, Starbucks shares volatile after report of potential takeover
- Why Citi says the Fed could be setting up for a dovish surprise
- Alphabet shares rise as Google pushes Gemini deeper into enterprise AI
Tweet
Share
E-mailGet Alerts DNTH Hot Sheet
Price: $82.74 -2.52%
Rating Summary:
17 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 18 | Down: 18 | New: 34
Rating Summary:
17 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 18 | Down: 18 | New: 34
Join SI Premium – FREE
H.C. Wainwright analyst Swayampakula Ramakanth raised the price target on Dianthus Therapeutics (NASDAQ: DNTH) to $130.00 (from $47.00) while maintaining a Buy rating.
You May Also Be Interested In
- Starbucks (SBUX) PT Lowered to $105 at UBS as Shares Already Reflect Improved Momentum
- HudBay Minerals (HBM:CN) (HBM) PT Raised to Cdn$46 at UBS
- First Quantum Minerals (FM:CN) (FQVLF) PT Raised to Cdn$60 at UBS
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
